Janux Therapeutics Inc (JANX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $13.80
• Market Cap: $824.02M
• EPS: $-1.67
• 52-Week High: $35.34
• 52-Week Low: $12.12

Market Sentiment

Janux Therapeutics Inc currently has a Bullish sentiment score of 0.53.

About Janux Therapeutics Inc

Janux Therapeutics, Inc. is an innovative biopharmaceutical company based in La Jolla, California, specializing in the development of advanced immunotherapies for cancer treatment through its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company aims to enhance patient outcomes by creating therapies that specifically target and eliminate tumor cells, addressing critical unmet needs in oncology. With a strong emphasis on T cell biology and tumor activation mechanisms, Janux...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Janux Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does JANX pay dividends?

Janux Therapeutics Inc (JANX) does not currently pay a regular dividend.

What is JANX's market cap?

Janux Therapeutics Inc (JANX) has a market capitalization of $824.02M with a current stock price of $13.80.